Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Remission Induction Therapy for Refractory Systemic Lupus Erythematosus With Autologous Hematopoietic Stem Cell Transplantation (AHSCT) Versus Rituximab (antiCD20) Followed by Maintenance Therapy With Mycophenolate Mofetil (MMF)

NCT05063513 is registered in ClinicalTrials.gov with European Society for Blood and Marrow Transplantation as lead sponsor.

NCT NCT05063513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05063513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Remission Induction Therapy for Refractory Systemic Lupus Erythematosus With Autologous Hematopoietic Stem Cell Transplantation (AHSCT) Versus Rituximab (antiCD20) Followed by Maintenance Therapy With Mycophenolate Mofetil (MMF)
Lead sponsor
European Society for Blood and Marrow Transplantation
Phase
Phase 2/3
Overall status
Withdrawn
Start date
July 31, 2009
Completion date
July 31, 2017
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory systemic lupus erythematosus